Secondary hyperparathyroidism due to hypovitaminosis D affects bone mineral density response to alendronate in elderly women with osteoporosis: A randomized controlled trial

Journal of the American Geriatrics Society

Volumn 55, Issue 5, 2007, Pages 752-757

  Barone, Antonella ^a   Giusti, Andrea ^a   Pioli, Giulio ^a   Girasole, Giuseppe ^b   Razzano, Monica ^a   Pizzonia, Monica ^a   Palummeri, Ernesto ^a   Bianchi, Gerolamo ^b  

^a GALLIERA HOSPITAL   (Italy)

^b Ospedale La Colletta   (Italy)

Author keywords

Alendronate; Bone mineral density; Osteoporosis; Secondary hyperparathyroidism; Vitamin D

Indexed keywords

ALENDRONIC ACID; CALCITRIOL; PARATHYROID HORMONE; VITAMIN D;

ABSENCE OF SIDE EFFECTS; ADULT; AGED; AGING; ARTICLE; BONE DENSITY; CALCIUM BLOOD LEVEL; CALCIUM URINE LEVEL; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DUAL ENERGY X RAY ABSORPTIOMETRY; FEMALE; FEMUR NECK; FOLLOW UP; HIP; HUMAN; LUMBAR SPINE; MAJOR CLINICAL STUDY; MONOTHERAPY; OSTEOPOROSIS; PARATHYROID HORMONE BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; SECONDARY HYPERPARATHYROIDISM; SIDE EFFECT; SINGLE BLIND PROCEDURE; STATISTICAL SIGNIFICANCE; TREATMENT RESPONSE; VITAMIN D DEFICIENCY;

AGED; ALENDRONATE; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; CALCITRIOL; CALCIUM; DENSITOMETRY, X-RAY; FEMALE; HUMANS; HYPERPARATHYROIDISM, SECONDARY; MIDDLE AGED; OSTEOPOROSIS, POSTMENOPAUSAL; PARATHYROID HORMONE; VITAMIN D DEFICIENCY;

EID: 34247627002     PISSN: 00028614     EISSN: 15325415     Source Type: Journal    
DOI: 10.1111/j.1532-5415.2007.01161.x     Document Type: Article

References (35)

1. Harris SS, Soteriades E, Coolidge JA et al. Vitamin D insufficiency and hyperparathyroidism in a low income, multiracial, elderly population. J Clin Endocrinol Metab 2000 85 : 4125 4130.
2. Chapuy MC, Schott AM, Garnero P et al. Healthy elderly French women living at home have secondary hyperparathyroidism and high bone turnover in winter. EPIDOS study group. J Clin Endocrinol Metab 1996 81 : 1129 1133.
3. Lips P, Duong T, Oleksik A et al. A global study of vitamin D status and parathyroid function in postmenopausal women with osteoporosis: Baseline data from the multiple outcomes of raloxifene evaluation clinical trial. J Clin Endocrinol Metab 2001 86 : 1212 1221.
4. Giusti A, Barone A, Razzano M et al. High prevalence of secondary hyperparathyroidism due to hypovitaminosis D in hospitalized elderly with and without hip fracture. J Endocrinol Invest 2006 29 : 809 813.
5. Von Muhlen DG, Greendale GA, Garland CF et al. Vitamin D, parathyroid hormone levels and bone mineral density in community-dwelling older women. The Rancho Bernardo Study. Osteoporos Int 2005 16 : 1721 1726.
6. Sigurdsson G, Franzson L, Steingrimsdottir L et al. The association between parathyroid hormone, vitamin D and bone mineral density in 70-year-old Icelandic women. Osteoporos Int 2000 11 : 1031 1035.
7. Lips P. Vitamin D deficiency and secondary hyperparathyroidism in the elderly: Consequences for bone loss and fractures and therapeutic implications. Endocrine Rev 2001 22 : 477 501.
8. Chapuy MC, Arlot ME, Duboeuf F et al. Vitamin D3 and calcium to prevent hip fractures in the elderly women. N Engl J Med 1992 237 : 1637 1642.
9. Ledger GA, Burritt MF, Kao PC et al. Role of parathyroid hormone in mediating nocturnal and age-related increases in bone resorption. J Clin Endocrinol Metab 1995 80 : 3304 3310.
10. Meunier FJ, Chapuy MC, Arlot ME et al. Can we stop bone loss and prevent hip fractures in the elderly? Osteoporos Int 1994 4 (Suppl 1) : S71 S76.
11. Pluijm SMF, Visser M, Smit JH et al. Determinants of bone mineral density in older men and women: Body composition as mediator. J Bone Miner Res 2001 16 : 2142 2151.
12. Meier C, Woitge HW, Witte K et al. Supplementation with oral vitamin D3 and calcium during winter prevents seasonal bone loss: A randomized controlled open-label prospective trial. J Bone Miner Res 2004 19 : 1221 1230.
13. Brown JP, Josse RG for the Scientific Advisory Council of the Osteoporosis Society of Canada: 2002 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada. Can Med Assoc J 2002 167 (Suppl 10) : S1 S34.
14. Kanis JA, Delmas P, Burckhardt P et al. Guidelines for diagnosis and management of osteoporosis. The European Foundation for Osteoporosis and Bone Disease. Osteoporos Int 1997 7 : 390 406.
15. Hodgson SF, Watts NB, Bilezikian JP et al. American Association of Clinical Endocrinologists 2001 medical guidelines for clinical practice for the prevention and management of postmenopausal osteoporosis. Endocr Pract 2001 7 : 293 312.
16. NIH Consensus Development Panel on Osteoporosis Prevention Diagnosis and Therapy. Osteoporosis prevention, diagnosis and therapy. JAMA 2001 285 : 785 795.
17. Ettinger B, Black DM, Mitlak BH et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: Results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. JAMA 1999 282 : 637 645.
18. Black DM, Reiss TF, Nevitt MC et al. Design of the Fracture Intervention Trial. Osteoporos Int 1993 3 (Suppl 3) : S29 S39.
19. Harris ST, Watts NB, Genant HK et al. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: A randomized controlled trial. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. JAMA 1999 282 : 1344 1352.
20. Rosen CJ, Hochberg MC, Bonnick SL et al. Treatment with once-weekly alendronate 70 mg compared with once-weekly risedronate 35 mg in women with postmenopausal osteoporosis: A randomised double-blind study. J Bone Miner Res 2005 20 : 141 151.
21. Cockcroft D, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976 16 : 31 41.
22. Eng J. Sample size estimation: How many individuals should be studied? Radiology 2003 227 : 309 313.
23. Cramer JA, Amonkar MM, Hebborn A et al. Compliance and persistence with bisphosphonate dosing regimens among women with postmenopausal osteoporosis. Curr Med Res Opin 2005 21 : 1453 1460.
24. Dawson-Hughes B, Harris SS, Krall EA et al. Effect of calcium and vitamin D supplementation on bone density in men and women 65 years of age or older. N Engl J Med 1997 337 : 670 676.
25. Chapuy MC, Pamphile R, Paris E et al. Combined calcium and vitamin D3 supplementation in elderly women: Confirmation of reversal of secondary hyperparathyroidism and hip fracture risk: The Decalyos II Study. Osteoporos Int 2002 13 : 257 264.
26. Sairanen S, Karkkainen M, Tahtela R et al. Bone mass and markers of bone and calcium metabolism in postmenopausal women treated with 1,25- dihydroxyvitamin D (calcitriol) for four years. Calcif Tissue Int 2000 67 : 122 127.
27. Pols HAP, Felsenberg D, Hanley DA et al. Multinational, placebo-controlled, randomized trial of the effects of alendronate on bone density and fracture risk in postmenopausal women with low bone mass. Results of the FOSIT Study. Osteoporos Int 1999 9 : 461 468.
28. Schnitzer T, Bone HG, Crepaldi G et al. Therapeutic equivalence of alendronate 70 mg once-weekly and alendronate 10 mg daily in the treatment of osteoporosis. Alendronate Once-Weekly Study Group. Aging (Milano) 2000 12 : 1 12.
29. Ishijima M, Yamanaka M, Sakamoto Y et al. Vitamin D insufficiency impairs the effect of alendronate for the treatment of osteoporosis in postmenopausal women [Abstract]. J Bone Miner Res 2005 20 (Suppl 1) : S296.
30. Koster JC, Hackeng WH, Mulder H. Diminished effect of etidronate in vitamin D deficient osteopenic postmenopausal women. Eur J Clin Pharmacol 1996 51 : 145 147.
31. Antoniucci DM, Vittinghoff E, Blackwell T et al. Vitamin D insufficiency does not affect bone mineral density response to raloxifene. J Clin Endocrinol Metab 2005 90 : 4566 4572.
32. Chapurlat RD, Palermo L, Ramsay P et al. Risk of fracture among women who lose bone density during treatment with alendronate. The Fracture Intervention Trial. Osteoporos Int 2005 16 : 842 848.
33. Thomas MK, Lloyd-Jones DM, Thadhani RI et al. Hypovitaminosis D in medical inpatients. N Engl J Med 1998 338 : 777 783.
34. Pettifor J. Nutritional and drug-induced rickets and osteomalacia. In : Favus M, ed. Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism, 5th Ed. Washington, DC : Lippincott Williams & Wilkins Publishers, 2004, pp 399 404.
35. Agrawal S, Krueger DC, Engelke JA et al. Between-meal risedronate does not alter bone turnover in nursing home residents. J Am Geriatr Soc 2006 54 : 790 795.